Celgene, Novartis Settle With Teva In Focalin IP Suits

By Brendan Pierson

Law360, New York (February 02, 2010, 2:14 PM ET) -- Celgene Corp. and Novartis Pharmaceuticals Corp. have settled a series of lawsuits against Teva Pharmaceuticals USA Inc. over its plan to market a generic version of attention deficit hyperactivity disorder treatment Focalin XR.

In stipulations filed in three separate lawsuits Monday in the U.S. District Court for the District of New Jersey, Celgene, Novartis and Teva agreed to dismiss all claims between them with prejudice. The parties will bear their own costs, according to the stipulations.

In December, the parties had filed stipulations asking the court...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles